Table 1 Baseline demographics and clinical characteristics of patients by different β-Blocker usage
From: Comparing the effects of various β-blockers on cardiovascular mortality in breast cancer patients
Variable | Metoprolol N = 3622 | Atenolol N = 1929 | Carvedilol N = 989 | Total N = 6540 | P-value |
|---|---|---|---|---|---|
N (%) | N (%) | N (%) | N (%) | ||
DEMOGRAPHIC VARIABLES | |||||
Age at index, in years | < 0.0001 | ||||
65–70 | 689 (19.02) | 465 (24.10) | 165 (16.68) | 1319 (20.17) | |
71–75 | 870 (24.02) | 456 (23.64) | 216 (21.84) | 1542 (23.58) | |
> 75 | 2063 (56.96) | 1008 (52.26) | 608 (61.48) | 3679 (56.25) | |
Race | < 0.0001 | ||||
White | 3177 (87.71) | 1685 (87.35) | 816 (82.51) | 5678 (86.82) | |
Black | 252 (6.96) | 108 (5.60) | 110 (11.12) | 470 (7.19) | |
Other | 171 (4.72) | 122 (6.32) | * | 352 (5.38) | |
Unknown | * | * | * | 40 (0.61) | |
Hispanic or Latino | 158 (4.36) | 87 (4.51) | 75 (7.58) | 320 (4.89) | 0.0001 |
Gender | 0.7066 | ||||
Female | 3595 (99.25) | * | * | 6487 (99.19) | |
Male | 27 (0.75) | * | * | 53 (0.81) | |
CLINICAL VARIABLES: | |||||
Charlson comorbidity Index | < 0.0001 | ||||
0 | 1429 (39.45) | 959 (49.72) | 209 (21.13) | 2597 (39.71) | |
1–3 | 1869 (51.60) | 870 (45.10) | 573 (57.94) | 3312 (50.64) | |
4 or greater | 324 (8.95) | 100 (5.18) | 207 (20.93) | 631 (9.65) | |
Statin use | < 0.0001 | ||||
Yes | 2163 (59.72) | 1104 (57.23) | 671 (67.85) | 3938 (60.21) | |
No | 1459 (40.28) | 825 (42.77) | 318 (32.15) | 2602 (39.79) | |
Breast Cancer stage | < 0.0001 | ||||
0 | 493 (13.61) | 291 (15.09) | 119 (12.03) | 903 (13.81) | |
I | 1532 (42.30) | 853 (44.22) | 351 (35.49) | 2736 (41.83) | |
II | 928 (25.62) | 484 (25.09) | 312 (31.55) | 1724 (26.36) | |
III | 274 (7.56) | 151 (7.83) | 98 (9.91) | 523 (8.00) | |
IV | 180 (4.97) | 75 (3.89) | 51 (5.16) | 306 (4.68) | |
Unknown | 215 (5.94) | 75 (3.89) | 58 (5.86) | 348 (5.32) | |
Diagnosed at breast cancer stage 0 or 1 | < 0.0001 | ||||
Yes | 2025 (55.91) | 1144 (59.31) | 470 (47.52) | 3639 (55.64) | |
No | 1597 (44.09) | 785 (40.69) | 519 (52.48) | 2901 (44.36) | |
Breast Cancer subtypes | 0.7382 | ||||
HR-/HER2+ | 193 (5.33) | 101 (5.24) | 44 (4.45) | 338 (5.17) | |
HR+/HER2- | 2256 (62.29) | 1217 (63.09) | 635 (64.21) | 4108 (62.81) | |
HR-/HER2- | 269 (7.43) | 125 (6.48) | 69 (6.98) | 463 (7.08) | |
HR+/HER2+ | 219 (6.05) | 114 (5.91) | 67 (6.77) | 400 (6.12) | |
Unknown | 685 (18.91) | 372 (19.28) | 174 (17.59) | 1231(18.82) | |
Breast Cancer as the only cancer | 0.7100 | ||||
Yes | 3191 (88.10) | 1685 (87.35) | 867 (87.66) | 5743 (87.81) | |
No | 431 (11.9) | 244 (12.65) | 122 (12.34) | 797 (12.19) | |